Aspen Neuroscience is pioneering personalized regenerative medicine by converting a patient’s own skin cells into induced pluripotent stem cells and then into dopaminergic neuronal precursor cells to treat neurodegenerative diseases. Its lead candidate, ANPD001, is the most advanced autologous cell therapy in the U.S. for moderate to advanced Parkinson’s disease and has received FDA Fast Track designation. The company’s proprietary manufacturing platform integrates machine-learning-based genomic testing for rigorous quality control and scalability, and it includes a precision MRI-guided delivery device for minimally invasive transplantation. Recent clinical progress includes initiation of Cohort 3 in a Phase 1/2a trial, with earlier cohorts showing favorable safety and clinician- and patient-reported improvements without the need for immunosuppression. Aspen plans to expand its pipeline to additional neurological indications while scaling manufacturing to meet future commercial demand. Headquartered in San Diego, the private company has raised more than $340 million to date, including an $8 million grant from the California Institute for Regenerative Medicine.

Total raised

$379M

Funding rounds

5

Latest round

Series C

Latest activity

Nov 2025